CMN548-M.5 EXAM QUESTIONS AND ANSWERS
WITH CORRECT SOLUTIONS LATEST 2026/2027 |
GRADED A+ | 100% PASS.
35.1.HTheHtime,Hcourse,HandHintensityHofHaHdrug'sHeffectHareHreferredHtoHas:
A.Hpharmacokinetics
B.Hpharmacodynamics
C.Hpharmacogenetics
D.HplaceboHeffect
E.HidiosyncraticHreactionH-HcorrectHanswer-B.Hpharmacodynamics
35.2.HNeuroleptic-inducedHmovementHdisordersHincludeHwhich ofHtheHfollowingHmovementHdisorders?
A.HAcuteHdystonia
B.HNeurolepticHmalignantHsyndrome
C.HAkathisia
D.HTardiveHdyskinesia
E.HAllHofHtheHaboveH-HcorrectHanswer-E.HAllHofHtheHabove
35.4.HTherapeuticHindicationsHofHβ-adrenergicHreceptorHantagonistsHsuchHasHpropranolol
(Inderal),HatenololH(Tenormin), metoprololH(Lopressor),HnadololH(Corgard),HandHpindolol
(Visken)HareHeffectiveHinHtheHtreatmentHof
A.HlithiumHtremor
B.HsubstanceHuseHdisorders
C.Hviolence
D.HperformanceHanxieties
E.HallHofHtheHaboveH-HcorrectHanswer-E.HallHofHtheHabove
, 35.5.HInHtheHelderlyHpopulation,HanticholinergicHmedications canHproduce
A.HimprovementHofHpositiveHsymptomsHofHpsychosis
B.HimprovedHstorageHofHnewHinformationHintoHlong-term memory
C.HworseningHideationalHapraxia
D.HimpairmentHinHcognitiveHfunctioning
E.HworseningHofHorientationHsubscalesH-HcorrectHanswer-D.HimpairmentHinHcognitiveHfunctioning
35.6.HNewerHanticonvulsantsHsuchHasHgabapentinH(Neurontin),
levetiracetamH(Keppra),HpregabalinH(Lyrica),Htiagabine
(Gabitril),HtopiramateH(Topamax),HandHzonisamideH(Zonegran)HhaveHdemonstratedHwhichHofHthe
followingHcharacteristics?
A.HEnhancingHneuronalHinhibition
B.HAnalgesicHeffects
C.HIncreasedHriskHofHsuicidality
D.HDecreasingHglutamicHfunction
E.HAllHofHtheHaboveH-HcorrectHanswer-E.HAllHofHtheHabove
35.3.HClonidineH(Catapres)HisHknownHtoHbeHeffectiveHin
A.HTourette'sHdisorder
B.Hattention-deficit/hyperactivityHdisorder
C.HopiateHwithdrawal
D.HposttraumaticHstressHdisorder
E.HallHofHtheHaboveH-HcorrectHanswer-E.HallHofHtheHabove
WITH CORRECT SOLUTIONS LATEST 2026/2027 |
GRADED A+ | 100% PASS.
35.1.HTheHtime,Hcourse,HandHintensityHofHaHdrug'sHeffectHareHreferredHtoHas:
A.Hpharmacokinetics
B.Hpharmacodynamics
C.Hpharmacogenetics
D.HplaceboHeffect
E.HidiosyncraticHreactionH-HcorrectHanswer-B.Hpharmacodynamics
35.2.HNeuroleptic-inducedHmovementHdisordersHincludeHwhich ofHtheHfollowingHmovementHdisorders?
A.HAcuteHdystonia
B.HNeurolepticHmalignantHsyndrome
C.HAkathisia
D.HTardiveHdyskinesia
E.HAllHofHtheHaboveH-HcorrectHanswer-E.HAllHofHtheHabove
35.4.HTherapeuticHindicationsHofHβ-adrenergicHreceptorHantagonistsHsuchHasHpropranolol
(Inderal),HatenololH(Tenormin), metoprololH(Lopressor),HnadololH(Corgard),HandHpindolol
(Visken)HareHeffectiveHinHtheHtreatmentHof
A.HlithiumHtremor
B.HsubstanceHuseHdisorders
C.Hviolence
D.HperformanceHanxieties
E.HallHofHtheHaboveH-HcorrectHanswer-E.HallHofHtheHabove
, 35.5.HInHtheHelderlyHpopulation,HanticholinergicHmedications canHproduce
A.HimprovementHofHpositiveHsymptomsHofHpsychosis
B.HimprovedHstorageHofHnewHinformationHintoHlong-term memory
C.HworseningHideationalHapraxia
D.HimpairmentHinHcognitiveHfunctioning
E.HworseningHofHorientationHsubscalesH-HcorrectHanswer-D.HimpairmentHinHcognitiveHfunctioning
35.6.HNewerHanticonvulsantsHsuchHasHgabapentinH(Neurontin),
levetiracetamH(Keppra),HpregabalinH(Lyrica),Htiagabine
(Gabitril),HtopiramateH(Topamax),HandHzonisamideH(Zonegran)HhaveHdemonstratedHwhichHofHthe
followingHcharacteristics?
A.HEnhancingHneuronalHinhibition
B.HAnalgesicHeffects
C.HIncreasedHriskHofHsuicidality
D.HDecreasingHglutamicHfunction
E.HAllHofHtheHaboveH-HcorrectHanswer-E.HAllHofHtheHabove
35.3.HClonidineH(Catapres)HisHknownHtoHbeHeffectiveHin
A.HTourette'sHdisorder
B.Hattention-deficit/hyperactivityHdisorder
C.HopiateHwithdrawal
D.HposttraumaticHstressHdisorder
E.HallHofHtheHaboveH-HcorrectHanswer-E.HallHofHtheHabove